A comparison of cenobamate with other newer antiseizure medications for adjunctive treatment of focal-onset seizures: A systematic review and network meta-analysis

Focal-onset seizures (FOS) in adults are controlled using anti-seizure medications (ASMs), with monotherapy being the gold standard for management of newly diagnosed epilepsies. Despite this optimal approach, over 50% of patients do not achieve seizure-free outcomes with initial monotherapy [1]. For these patients, use of alternative monotherapies followed by combination therapies using an additional ASM as an adjunctive is recommended [1,2]. Drug-resistant epilepsy affects a significant portion of the epilepsy population [3], and it can be challenging to manage seizures with conventional medications, thus, underscoring the critical need for ongoing research and development of new therapies to address this unmet medical challenge.

Source: Seizure: European Journal of Epilepsy - April 5, 2024 Category: Neurology Authors: Stuart Mulheron, Thomas P. Leahy, Megan McStravick, Rachael Doran, Norman Delanty Source Type: research